AB-161 / Arbutus - LARVOL DELTA

Structure-Activity Relationships and Discovery of (S)-5-(tert-Butyl)-11-(difluoromethoxy)-9-methoxy-2-oxo-1,2,5,6-tetrahydropyrido[2',1':2,3]imidazo[4,5-h]quinoline-3-carboxylic Acid (AB-161), a Novel Orally Available and Liver-Centric HBV RNA Destabilizer. (PubMed, J Med Chem) - "There were no neurobehavioral effects with AB-161 in dogs up to 45 mg/kg after 60 days, unlike with AB-452, where these were observed at lower doses by day 14. AB-161 was then advanced into 90-day GLP toxicology studies, where the improved neurotoxicity profile persisted, but reproductive issues emerged, leading to discontinuation."

Journal • Hepatitis B • Hepatology • Infectious Disease • Inflammation • Pain

Preclinical Antiviral and Safety Profiling of the HBV RNA Destabilizer AB-161. (PubMed, Viruses) - "However, all nerve conduction metrics remained within physiologically normal ranges, with no neurobehavioral or histopathological findings. Despite the improved neurotoxicity profile, microscopic findings associated with male reproductive toxicity were detected in dogs, which subsequently led to the discontinuation of AB-161's clinical development."

Journal • Preclinical • Hepatitis B • Hepatology • Infectious Disease • Inflammation

A Study of AB-161 Following Oral Administration in Healthy Subjects (ANZCTR) - P1 | N=90 | Terminated | Sponsor: Arbutus Biopharma Corporation | Completed ➔ Terminated

Trial termination • Hepatitis B • Hepatology • Infectious Disease • Inflammation

A Study of AB-161 Following Oral Administration in Healthy Subjects (ANZCTR) - P1 | N=90 | Completed | Sponsor: Arbutus Biopharma Corporation | Not yet recruiting ➔ Completed | Initiation date: Mar 2023

Trial completion • Trial initiation date • Hepatitis B • Hepatology • Infectious Disease • Inflammation

Arbutus Announces 2022 Corporate Objectives and Provides Financial Update (GlobeNewswire) - "Summary of 2022 Anticipated Key Milestones:...Announce preliminary AB-729 data in the second half of 2022 from the following three on-going Phase 2a proof-of-concept clinical trials in patients with chronic hepatitis B (HBV) infection:...Initiate a triple combination Phase 2a proof-of-concept clinical trial in the first half of 2022 to evaluate AB-729, combined with VTP-300, Vaccitech’s therapeutic vaccine, and a NA. Present at a medical conference the long-term on- and off-treatment follow-up data from our Phase 1a/1b clinical trial evaluating multiple doses and dosing schedules of AB-729. Announce data from our Phase 1a/1b clinical trial evaluating AB-836 in patients with chronic HBV in the first half of 2022. Complete IND-enabling studies with our oral PD-L1 inhibitor compound, AB-101, in the second half of 2022. Complete IND-enabling studies for AB-161, our next-generation oral HBV specific RNA destabilizer, in the second half of 2022."

New P2a trial • P1 data • P2a data • Preclinical • Hepatitis B • Infectious Disease